leukemia, neoplasm, chromosome aberrations, Philadelphia chromosome, trisomy, fluorescence in situ hybridization, Reverse Transcriptase Polymerase Chain Reaction

[1] Hochman MJ, Smith BD, Karantanos T, Braunstein EM, Gojo I, Jain T, Streiff MB, Moliterno AR, Dezern AE. Chronic myeloid leukemia (CML) evolves from Philadelphia chromosomenegative myeloproliferative neoplasms (MPNs) with unexpected frequency. International Journal Hematology. 117(3):456-462, 2023.
doi: 10.1007/s12185-022-03463-0
[2] Dávila-Rodríguez MI., Cerda-Flores RM., Leal-Garza CH., Arana-Trejo RM., Báez-Fuente E, Cortés-Gutiérrez EI. Alteraciones cromosómicas secundarias en pacientes con leucemia mieloide crónica, en un hospital de referencia del noreste de México. Gaceta Médica México.
140(6): 589-592, 2004.
[3] Pavón V, Hernández P, Martínez G, Agramonte- lanes O, Jaime JC, Bravo-Regueiro J. Leucemia mieloide crónica: Actualización en Citogenética y Biología Molecular. Revista Cubana Hematología Inmunología y Hemoterapia. 21(2):1-10, 2005.
[4] Chávez-González MA, Ayala-Sánchez M, Mayani H. La leucemia mieloide crónica en el siglo XXI: biología y tratamiento. Revista de Investigación. Clinica. 61(3): 221-232, 2009.
[5] Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. The biolgy of chronic myeloid leukemia. New England Journal Medicine. 341(3): 164-172, 1999.
doi: 10.1056/NEJM199907153410306
[6] Buda G, Orciuolo E, Galimberti S, Benedetti E, Caracciolo F, Cervetti G, Carulli G, Papineschi F, Petrini M. Complex Translocation t (3;9;22) (q21; q34; q11) at diagnosis is a negative prognostic index in Chronic Myeloid Leukemia. Leukemia Research. 32(1):192-194,2008.
doi: 10.1016/j.leukres.2007.02.007
[7] Richebourg S, Eclache V, Perot C, Portnoi M, Van den Akker J, Terré C, Maareck O, Soenen V, Viguié F, Laï JC, Andrieux J, Corm S. Mechanisms of Genesis of Variant Translocation in Chronic Myeloid Leukemia are not correlated with ABL1 or BCR deletion status or response to Imatinib therapy. Cancer Genetics and Cytogenetics. 182(2): 95-102. 2018.
doi: 10.1016/j.cancergencyto.2008.01.005
[8] Li Q, Lin XJ, Chen H, Gong J, Li Z, Chen XN. Co-Existence of Isodicentric Ph Chromosomes and the Three-Way Ph Chromosome Variant t (3;9;22) (P21; Q34; Q11) in a Rare Case of Chronic Myeloid Leukemia. Oncology Letters. 15(4): 4599-4603, 2018.
doi: 10.3892/ol.2018.7866
[9] Davila-Rodriguez MI. Caracterización citogenética y molecular de un grupo de pacientes con Leucemias Mieloide Crónica en el Noreste de México [Tesis de Doctorado]. México: Universidad Autónoma de Nuevo Leon, Facultad de Ciencias Biológicas; 2001.
URL: http://cdigital.dgb.uanl.mx/te/1080124434.PDF
[10] Zaccaria A, Testoni N, Valenti A, Luatti S, Tonelli M, Marzocchi G, Cipriani R, Baldazzi C, Giannini B, Stacchini M, Gamberini C, Castagnetti F, et al. Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. Cancer Genetics and Cytogenetics. 199(2): 76-80,2010.
doi: 10.1016/j.cancergencyto.2010.02.003
[11] Chomel JC, Brizard F, Veinstein A, Rivet J, Sadoun A, Kitzis A, Guilhot F, Brizard A. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation. Blood. 95(2): 404-408, 2000.
doi: 10.1182/blood.v95.2.404
[12] Zhang Z, Chen Z, Jiang M, Liu S, Guo Y, Wan L Li F. Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia. BMC Cancer. 19(935),2019.
doi: 10.1186/s12885-019-6137-8
[13] Lee DS, Kim EC, Yoon BH, Kim WH, Yoon JH, Cho H. Can minor bcr/abl translocation in acute leukemia be discriminated from major bcr/abl by extra-signal FISH analysis? Haematologica. 86(9): 991-992, 2001.
[14] Primo D, Tabernero MD, Rasillo A, Sayagués JM, Epinosa AB, Chillón MC, Garcia-Sanz R, Gutierrez N, Geralt M, Hagemeijer A, San-Miguel JF, Orfao A. Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+leukemias: Incidence and underlying genetic abnormalities. Leucemia. 17(6): 1124-1129,2003.
doi: 10.1038/sj.leu.2402963
[15] Bianchini M, Larripa I. Cuantificación de los transcriptos BCR-ABL1 y evaluación de la respuesta molecular en Leucemia Mieloide Crónica. Hematología. 18(2): 164-168, 2014.
URL: https://ri.conicet.gov.ar/handle/11336/36289
[16] Hughes TP, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross-Nicholas CP, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton- Jeffrey H, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM. Monitoring CML patients responsing to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts
and kinase domain mutations and for expressing results. Blood. 108(1): 28-37, 2006.
doi: 10.1182/blood-2006-01-0092
[17] Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O’Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, Radich JP. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 116 (19): 3758–3765. 2010.
doi: 10.1182/blood-2010-03-273979
[18] Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein BG, Haferlach C, Göhring G, Schlegelberger B, Jotterand M, Reiter A, Jung-Munkwitz S, Proetel U, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: Long-term observation of 1151 patients from the randomized CML Study IV. Blood. 118(26): 6760–6768, 2011.
doi: 10.1182/blood-2011-08-373902
[19] Otero L, Ornellas M, Mello A, Dobbin J, Abdelhay E, Bouzas LF, Fernandez T. The Impact of Additional Chromosomal Abnormalities in Response to ImatinibMesylate Therapy for Chronic Myeloid Leukemia. Bras Cancerologia. 53(4): 405-410, 2007.
doi: 10.32635/2176-9745.RBC.2007v53n4.1770
[20] Rodríguez M, Cardona A F, Grajales MA, Enciso L, Ruiz G, Yepes A, Ospina V, Gálvez K, García J, Rosales J, Rosales M, Quintero G, Rosales C, Timana J, Casas CP, Combariza JF, Vargas E, Molano A. Leucemia mieloide crónica en crisis blástica. Bases moleculares y diagnostico. Revista Venezolana de Oncología [Internet]. 19(4):287-296, 2007.
URL: https://www.redalyc.org/articulo.oa?id=375635139003
[21] Au WY, Caguioa PB, Chuah C, Hsu SC, Jootar S, Kim D, Kweon IY, O’Neil WM, Saika TP, Wang J. Chronic myeloid leukemia in Asia. International Journal Hematology. 89: 14-23, 2009.
doi: 10.1007/s12185-008-0230-0
[22] Safaei A, Monabati A, Safavi M, Atashabparvar A, Hosseini M. Additional cytogenetic aberrations in chronic myeloid leukemia: A single-center experience in the Middle East. Blood Research. 53(1): 49–52, 2018.
doi: 10.5045/br.2018.53.1.49
[23] Björk J, Mikoczy Z, Ahlgren T, Nilsson PG, Mitelman F, Hagmar L, Albin M, Welinder H, Tinnerberg H, Mauritzson N, Kauppinen T, Strömberg U, Johansson B, Billström R. Are occupational, hobby, or lifestyle exposures associated with Philadelphia chromosome positive chronic myeloid leukaemia? Occupational and Environmental Medicine. 58(11):722-727, 2001.
doi: 10.1136/oem.58.11.722
[24] Radivoyevitch T, Jankovic GM, Tiu RV, Saunthararajah Y, Jackson RC, Hlatky LR, Gale RP, Sachs RK. Sex differences in the incidence of chronic myeloid leukemia. Radiation and Environmental Biophysics. 53: 55–63, 2014.
doi: 10.1007/s00411-013-0507-4
[25] Vardiman JW, Melo JV, Baccarani M, Thiele J. Myeloproliferative Neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press. 32-37,2008.
[26] Simons CM, Stratton CW, Kim AS. Peripheral blood eosinophilia as a clue to the diagnosis of an occult Coccidioides infection. Human Pathology. 42: 449-453, 2011.
doi: 10.1016/j.humpath.2010.09.005
[27] Ujjan I, Akhund1 AA, Baig AM, Nizamani GS. The cytogenetic and molecular analysis of chronic myeloid leukemia in a tertiary care hospital of Sindh, Pakistan. Integrative Cancer Science and Therapeutics. 2(3): 164-167, 2015.
doi: 10.15761/ICST.1000133
[28] Mysorekar VV, Subramanian M, Kilara N, Sundareshan TS. Variant Philadelphia translocations in chronic myeloid leukemia: A report of five cases. Journal of Cancer Research and Therapeutics. 11(3): 654, 2015.
doi: 10.4103/0973-1482.138036
[29] Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematologica. 2002 107(2): 76-94, 2015.
doi: 10.1159/000046636
[30] Mkrtchyan H, Ghazaryan S, Avetisyan A, Hovhannisyan A, Muradyan L, Daghbashyan S, Karts C, Gross M, Hinreiner S, Aroutiounian R, Liehr T. Novel complex t(V;9;22) rearrangements in three cases with chronic myeloid leukemia and a rare translocation in a case with classical Philadelphia chromosome. Oncology Reports. 20: 99–104, 2008.
doi: 10.3892/o.20.1.99
[31] Marzocchi G, Castagnetti F, Luatti S, Baldazzi C, Stacchini M, Gugliotta G, Amabile M, Specchia G, Sessarego M, Guissani U, et al. Variant Philadelphia translocations: Molecular‑cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. Blood. 117(25): 6793‑6800, 2011.
doi:10.1182/blood-2011-01-328294
[32] Barbata G, Granata G, Bellanca F, Mórdica L, Carbono P. Complex translocation t(3;9;22) and paracentric inversion of chromosome 3 in blastic crisis of chronic myeloid leukemia. Cancer Genetic and Cytogenetic. 20(3-4): 305–309, 1986.
doi: 10.1016/0165-4608(86)90088-9
[33] Albano F, Anelli L, Zagaria A. Coccaro N, Casieri P, Rossi AR, Vicari L, Liso V, Rocchi M, Specchia G. Non-random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements. Molecular Cancer. 9:120, 2010.
doi: 10.1186/1476-4598-9-120
[34] Robledo C, García JL, Benito R, Flores T, Mollejo M, Martínez-Climent JA, García E, Gutiérrez NC, Piris MA, Hernández JM. “Molecular Characterization of the Region 7q22.1 in Splenic Marginal Zone Lymphomas.” PLoS ONE. 6(9), 2011: E24939.
doi: 10.1371/journal.pone.0024939
[35] Millot F, Dupraz C, Guilhot J, Suttorp M, Brizard F, Leblanc T, Günes AM, Sedlacek P, De-Bont E, Li CK, et al. Additional cytogenetic abnormalities and variant t (9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents. Cancer. 123(18):
3609–3616, 2017.
doi: 10.1002/cncr.30767
[36] Al-Achkar W, Wafa A, Moassass F, Liehr T. A chronic myeloid leukemia case with a unique variant Philadelphia translocation: t(9;22;21)(q34;q11;p12). Oncology Letters. 3(5):1027-1029, 2012.
doi: 10.3892/ol.2012.623
[37] Ramachandran KC, Narayanan G, Murugesan SK, Kumar RS, Krishna KM, Sreedharan H. Impact of Additional Chromosomal Aberrations on the Disease progression of Chronic Myelogenous Leukemia. Frontiers in Oncology. 9(88). 2234-943, 2019.
doi:10.3389/fonc.2019.00088
[38] Acar, Kadir, and Burak Uz. “A chronic myeloid leukemia case with a variant translocation t(11;22) (q23;q11.2): masked Philadelphia or simple variant translocation?.” The Pan African medical jornal. 30(161), 2018.
doi: 10.11604/pamj.2018.30.161.9318
[39] Ali R, Ozkalemkas F, Ozkocaman V, Yakut T, Nazlioglu HO, Budak F, Pekgoz M., Korkmaz S, Karkucak M, Ozcelik T, Tunali A. Sudden blastic crisis and additional chromosomal abnormalities duringchronic myeloid leukemia in the Imatinib era. International Journal of Clinical Oncology. 14: 545-550, 2009.
doi: 10.1007/s10147-009-0884-5
[40] Alhuraiji1 A, Kantarjian H, Boddu P, Ravandi F, Borthakur G, DiNardo C, Davar N, Kadia T, Pemmaraju N, Pierce S, Garcia-Manero G, Wierda W, Verstovsek S, Jabbour E, Cortes J. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. American Jorunal of Hematology. 93(1):84-90, 2018.
doi: 10.1002/ajh.24943
[41] Dorfman LE, Floriani MA, Oliveira TMR, Cunegatto B, Rosa R, Zen P. The role of cytogenetics and molecular biology in the diagnosis, treatment and monitoring of patients with chronic myeloid leukemia. Jorunal Brasileiro de Patologia e Medicina Laboratorial. 54(2):83-91, 2018.
doi: 10.5935/1676-2444.20180015
[42] Beligoy L, Bendek G, Bengió R, Bullorky L, Enrico A, Franceschi E, et al. Guías de Diagnóstico y Tratamiento. Ed. 2019. Argentina: Sociedad Argentina de Hematología,461-480, 2019.
[43] Wang W, Cortes JE, Tang G, Khoury JD, Wang S, Bueso-Ramos CE, Digiuseppe JA, Chen Z, Kantarjian HM, Medeiros LJ, Hu S. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 127(22):2742–2750, 2016.
doi: 10.1182/blood-2016-01-690230
[44] Vargas MT, Fernández-Novoa MC, García-Creus MD, González J. Trisomía 8 en dos casos de leucemia mieloide crónica ABL/BCR negativo. Revista médica de Chile. 130(4): 460-462,2002.
doi: 10.4067/S0034-98872002000400015
[45] Schoch C, Haferlach T, Kern W, Schnittger S, Berger U, Hehlmann R, Hiddemann W, Hochhaus A. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated witn imatinib mesylate. Leukemia. 17: 461–463, 2003.
doi: 10.1038/sj.leu.2402813
[46] Fioretos T, Johansson B. Chronic Myeloid Leukemia. En: Heim S, Mitelman F. Cancer Cytogenetics. 3a ed. New Jersey: John Wiley y Sons, Inc, 3: 179-207, 2009.
[47] Roche-Lestienne C, Deluche L, Corm S, Tigaud I, Joha S, Philippe N, Greffroy S, Laï Jl, Nicolini FE, Preudhomme C. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL1 + leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and Imatinib resistance. Blood. 111(7): 3735-3741,2008.
doi: 10.1182/blood-2007-07-102533
[48] Calabrese G, Di Bartolomeo P, Stuppia L, et al. Citogenética en pacientes con leucemia mielógena crónica tratados con trasplante de médula ósea. Genética y citogenética del cáncer. 41(1): 49–59, 1989.
doi: 10.1016/0165-4608
[49] Deluche L, Joha S, Corm S, Daudignon A, Geffroy S, Quief S, Villenet C, Kerckaert JP, Laï JL, Preudhomme C, Roche-Lestienne C. Cryptic and partial deletions of PRDM16 and RUNX1 without t (1;21) (p36; q22) and/or RUNX1-PRDM16 fusion in a case of progressive chronic myeloid leukemia: A complex chromosomal rearrangement of underestimated frequency in disease progression? Genes, Chromosomes and Cancer. 47 (12): 1110-1117,2008.
doi: 10.1002/gcc.20611
[50] Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, Kohlbrenner K, Haferlach C, Schlegelberger B, Fabarius A, Seifrath W, Spieb B. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia. 2020.
doi: 10.1038/s41375-020-0826-9
[51] Hernández-Aguilar N, Lavaut-Sánchez K, Ruiz-Moleón V. Patrones de hibridación del gen de fusión BCR/ABL1 en pacientes cubanos con leucemia. Revista Cubana Hematologica Inmunologica Hemoterapia. 32(2):215-222, 2016.
URL: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892016000200006&lng=es
[52] Wan TSK, Ma SK, Au WY, Chan LC. Derivative chromosome 9 deletions in chronic myeloid leukaemia: interpretation of atypical D-FISH pattern. Jorunal of Clinical Pathology. 56(6):471-474, 2003.
doi: 10.1136/jcp.56.6.471
[53] Sinclair PB, Nacheva EP, Leversha M, Terford N, Chang L, Reid A, Bench A, Champion K, Huntly B, Green AR. Large deletions at the t (9;22) breakpoint are commonand may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood. 95(3):738-743,2000.
[54] Huntly BJ, Reid AG, Bench AJ, Bench AJ, Campbell LJ, Telford N, Shepherd P, Szer J, Miles PH, Turner P, Grace C, Nacheva EP, Green AR. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood. 98: 1732-1738, 2001.
doi: 10.1182/blood. v98.6.1732
[55] Kolomietz E, Al-Maghrabi J, Brennan S, Karaskova J, Minkin S, Lipton J, Squire JA. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood. 97(11): 3581-3588,2001.
doi: 10.1182/blood.v97.11.3581
[56] Cohen N, Rozenfeld-Granot G, Hardan Y, Brok-Simoni B, Amariglio N, Rechavit G, Trakhtenbrot L. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genetics and Cytogenetics. 128: 114-119,2001.
doi: 10.1016/s0165-4608(01)00412-5
[57] Chase A., Huntly B. J., Cross N.C. Cytogenetics of chronic myeloid leukaemia. Best pactice and Research. Clinical Haematology. 14(3): 553-571, 2001.
doi: 10.1053/beha.2001.0154
[58] Comert M, Baran Y, Saydam G. Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era. American Journal Blood Research. 3(3): 191-200, 2013.
[59] Morel F, Ka C, Le-Bris MJ, Herry A, Morice P, Bourquard P, Abgrall JF, Berthou C, De-Braekeleer M. Deletion of the 5'ABL region in Philadelphia chromosome positive chronic myeloid leukemia : frequency, origin and prognosis. Leukemia and Lymphoma. 44: 1333-8,2003.
doi: 10.1080/1042819031000097384
[60] Prejzner W. Relationsship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia. Medical Sciencie Monitor. 8(5): 193-197, 2002.
[61] Quintas-Cardama A, Cortes JA. Chronic myeloid leukemia diagnosis and treatment. Mayo Clin. Proc. 81(7): 973 988, 2006.
doi: 10.4065/81.7.973
[62] Cañizález JZ, Rojas-Atencio A, Urdaneta K, Atencio-Rojas R, González R, Soto M., Villalobos Y. Transcritos del gen BCR-ABL, en pacientes con leucemia mieloide crónica en Venezuela. SABLE. Revista Multidisciplinaria del Consejo de Investigación de la Universidad de Oriente. 27(3):422-429, 2015.
URL: https://www.redalyc.org/articulo.oa?id=427743080008
[63] Epstein FH, Kurzrock R, Gutterman J, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. New England Journal of Medicine. 319(15): 990-998,1988.
doi: 10.1056/NEJM198810133191506
[64] Cross N, Hughes T, Feng L, O’Shea P, Bungey J, Marks DI, Ferrant A, Martiat P, Goldman JM. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlation with acute graft-versus-host disease and relapse. British Journal of Haematology. 84(1): 67-74, 1993.
doi: 10.1111/j.1365-2141.1993.tb03026.x
[65] Artigas CG, Melo A, Roa JC, Páez E, Vittini C, Arriagada M, González L, Pflaumer E, Roa I. Detección de secuencias del gen BCR-ABL mediante RT-PCR en pacientes con leucemia en la IX Región: Chile. Revista médica de Chile.130(6): 623-630, 2002.
doi: 10.4067/S0034-98872002000600004
[66] Amor-Vigil AM, González-Medina Y, Cayado-Gutiérrez N, Martínez-Antuña G. Frecuencia de transcritos de BCR-ABL en pacientes cubanos con leucemia mieloide crónica. Revista Cubana Hematología Inmunología Hemoterapia. 2012;28 (4):428-434, 2012.

Vol. 28 No. 3 (2023)